Fenton Mary Kay Insider Trades

Insider Trading History

Track insider trading activity for Fenton Mary Kay. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Cullinan Therapeutics
Cullinan Therapeutics CGEM
Chief Financial Officer
Holding Value $1.82M 126,380 shares
Last Trade
Feb 20, 2026 Sale (Open Market)Shares sold on the open market or in a private sale.
$59.9k 4,398 shares
$13.62
$14.43
Cullinan Therapeutics
Cullinan Therapeutics CGEM
Chief Financial Officer
Holding Value $1.98M 137,500 shares
Last Trade
Feb 18, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.57M 206,250 shares
$12.44
$14.43
Cullinan Therapeutics
Cullinan Therapeutics CGEM
Chief Financial Officer
Holding Value $895k 62,028 shares
Last Trade
Dec 31, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$279 27 shares
$10.35
$14.43
Cullinan Therapeutics
Cullinan Therapeutics CGEM
Chief Financial Officer
Holding Value $1.73M 120,000 shares
Last Trade
Feb 19, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.13M 120,000 shares
$9.43
$14.43
Cullinan Therapeutics
Cullinan Therapeutics CGEM
Chief Financial Officer
Holding Value $2.89M 200,000 shares
Last Trade
Apr 29, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$5.42M 200,000 shares
$27.12
$14.43
Tourmaline Bio
Tourmaline Bio TRML
Chief Financial Officer
Holding Value $3.27M 68,054 shares
Last Trade
Jul 03, 2023 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$413k 12,946 shares
$31.90
$47.98
Talaris Therapeutics
Talaris Therapeutics TALS
Chief Financial Officer
Holding Value $185k 68,054 shares
Last Trade
Jul 03, 2023 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
No data
No data
$2.72
Talaris Therapeutics
Talaris Therapeutics TALS
Chief Financial Officer
Holding Value $408k 150,000 shares
Last Trade
Feb 01, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$2.72
Talaris Therapeutics
Talaris Therapeutics TALS
Chief Financial Officer
Holding Value $220k 81,000 shares
Last Trade
Sep 10, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$2.72
Oncorus
Oncorus ONCR
Director
Holding Value $1.58k 12,500 shares
Last Trade
Jun 23, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$20k 12,500 shares
$1.60
$0.13
Talaris Therapeutics
Talaris Therapeutics TALS
Chief Financial Officer
Holding Value $544k 200,000 shares
Last Trade
Feb 01, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$2.72
Talaris Therapeutics
Talaris Therapeutics TALS
Chief Financial Officer
Holding Value $2.72k 1,000 shares
Last Trade
Dec 31, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$2.72
Oncorus
Oncorus ONCR
Director
Holding Value $1.58k 12,500 shares
Last Trade
Jun 16, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$207k 12,500 shares
$16.55
$0.13
Talaris Therapeutics
Talaris Therapeutics TALS
Chief Financial Officer
Holding Value $0 0 shares
Last Trade
May 06, 2021 Sale
No data
No data
$2.72
Oncorus
Oncorus ONCR
Director
Holding Value $0 0 shares
Last Trade
Oct 01, 2020 Sale
No data
No data
$0.13

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up